An innovative drug designed to regenerate spinal discs is in the final stages of a large trial, offering hope for a lasting solution to chronic low back pain. If successful, this once-and-done injection could redefine treatment options for millions affected worldwide.
- Phase 3 trial treating 350 participants with a single intra-discal injection.
- Drug aims to rebuild spinal discs and ease chronic low back pain.
- Final 12-month results expected by mid-2027.
What happened
Mesoblast, an Australian biotechnology company, recently announced the completion of patient dosing in its pivotal Phase 3 clinical trial testing rexlemestrocel-L for chronic low back pain (CLBP). The trial originally planned for 300 participants but expanded to 350 due to high demand. Half of these patients received the active drug injection, while the other half were given a sham control shot.
This carefully designed study aims to evaluate long-term pain reduction, improved mobility, better quality of life, and a reduced need for other pain medications. Patients have been monitored for 12 months following treatment to assess how well the drug performs compared to traditional therapies.
Why it feels good
Chronic low back pain resulting from degenerative disc disease is a widespread condition leading to discomfort and disability for many adults worldwide. Current treatments largely focus on managing symptoms rather than repairing the underlying damage to spinal discs, which are crucial shock absorbers between vertebrae.
Rexlemestrocel-L offers a promising new approach by using regenerative medicine to potentially restore these worn discs. By addressing the root cause, this one-shot therapy could deliver lasting relief and improve daily function, transforming life for millions who struggle with persistent back pain.
What to enjoy or watch next
All patients in the trial will be monitored until 12 months post-treatment, with full study results expected by mid-2027. These results will reveal whether rexlemestrocel-L can meet its goals and qualify for expedited FDA review under a special regenerative medicine designation.
Beyond low back pain, rexlemestrocel-L is also being investigated for heart failure, showing the broad potential of this therapy. For those interested in medical innovations and advances in chronic pain management, this trial’s outcome will be a key development to watch closely.